Research programme: neoantigen-based cancer vaccines - Imunon
Alternative Names: IP-Y; IP-Y - ImunonLatest Information Update: 24 May 2023
At a glance
- Originator Imunon
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 May 2023 Early research in Cancer in USA (unspecified route) before May 2023 (Imunon pipeline, May 2023)